Posts tagged marketing partner
HHS to expand treatment access for war on opioid addiction

Titan Pharmaceuticals (NASDAQ:TTNP) and its marketing partner, closely-held Braeburn Pharmaceuticals, received a potential shot in the arm as the White House called for expanded access to treatment in the war on opioid addition.

Read More
Titan Pharma’s Kate Beebe interviewed on Facebook Live

Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP), was interviewed on Facebook Live yesterday in conjunction with the company ringing the closing bell at the exchange.

Dr. Beebe discussed Titan’s Probuphine implant, which was approved by the FDA earlier this year for the treatment of opioid addiction, and its sales and marketing partner, Braeburn Pharmaceuticals.

Read More
Titan’s Probuphine featured at ISAM meeting

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant and marketing partner, closely-held Braeburn Pharmaceuticals, were featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week.

Probuphine, a subdermal implant of buprenorphine, is the first commercially available six-month maintenance treatment for opioid dependence. The FDA approved Probuphine in May.

Read More
Buprenorphine patient limit raised to 275

The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine.

The move was part of several announced by the administration as part of an effort to stem the opioid abuse epidemic that is killing nearly 80 people from overdoses every day.

Read More